Guardant Health, Inc. · NASDAQ:GH
Guardant Health — Jefferies London Healthcare Conference 2023
28 slides from Guardant Health's conference presentation, Nov 16, 2023
Slide 1: Transforming Cancer Care
Transforming Cancer Care Jefferies London Healthcare Conference November 16, 2023
Slide 2: Safe harbor
Safe harbor Certain statements in this presentation and the accompanying oral commentary are forward-looking projections are reasonable, such forward-looking statements are only predictions and involve known and statements within the meaning of federal securities laws. These statements relate to fut
Slide 3: Guardant Health was founded with the mission to give us all more time free from cancer
Guardant Health was founded with the mission to give us all more time free from cancer 3
Slide 4: Guardant Health pioneered liquid biopsy
Guardant Health pioneered liquid biopsy Novel Next-generation AI-powered Patient biochemistry sequencing techniques bioinformatics report 4
Slide 5: Transforming patient lives across the continuum of cancer care
Transforming patient lives across the continuum of cancer care Screening Minimal Residual Disease Therapy Selection Early Disease Detection Recurrence Detection & Surveillance Advanced Cancer Care $100B >120M $20B >15M $10B >700K Average-Risk Early-Stage Patients Advanced Individuals and Survivors C
Slide 6: Guardant today
Guardant today $555M 160+ 60+ 600+ 2023 Revenue Biopharma Countries Global Patents & Guidance Midpoint1 Partners Patent Applications 1 FY 2023 Revenue guidance of $553 - $556M updated November 6, 2023 6
Slide 7: Leading in liquid biopsy for Therapy Selection
Leading in liquid biopsy for Therapy Selection
Slide 8: Significant untapped potential in the Therapy Selection market
Significant untapped potential in the Therapy Selection market 700K Total Patients $10B Total Addressable Market Sources: Therapy selection TAM is Stage IV patients., Data from internal modeling that sources information from US Cancer Statistics; SEER, CancerMPact®, NODA data, Treatment 8 Architectu
Slide 9: Actionable information and speed saves patient lives
Actionable information and speed saves patient lives Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer 4x Better patient outcomes with CGP testing Every month delayed in cancer treatment can raise ri
Slide 10: Comprehensive portfolio for Therapy Selection with broad payer coverage
Comprehensive portfolio for Therapy Selection with broad payer coverage 1st FDA-Approved Next-Generation 1st Blood-Only Next-Generation Comprehensive Liquid Biopsy Liquid Biopsy Tissue Assay Liquid Biopsy Assay to Monitor Tx Response Reimbursed by Medicare Guardant internal data on file 9
Slide 11: Guardant360 has been the primary volume growth driver
125K 88K 50K 63K 44% Clinical Testing 29K Volume CAGR Guardant360 has been the primary 2018 2019 2020 2021 2022 volume growth driver 26K 21K 26% 19K 16K 10K Biopharma Testing Volume CAGR 2018 2019 2020 2021 2022 11
Slide 12: Therapy Selection utilization will continue to grow
Therapy Selection utilization will continue to grow Increase liquid and Unlock new actionable Physicians are using CGP tissue adoption biomarkers and use cases testing in earlier lines #1 Rated Field Team1 #1 Rated Support1 #1 In-Person Share of Voice1 #1 Remote Share of Voice1 12
Slide 13: Therapy Selection has multiple growth drivers well beyond 2023
Therapy Selection has multiple growth drivers well beyond 2023 Portfolio ASP Market expansion increases Future Guardant360 Infinity offering to CDx approvals biopharma partners TissueNext & International expansion, Response attachment e.g., Japan, UK, China Therapy Selection on track to be cash flow
Slide 14: Paving the way for tissue-free MRD
Paving the way for tissue-free MRD
Slide 15: The only tissue-free MRD test available clinically
$20B+ The only tissue-free MRD U.S. market in test available clinically early development Currently in CRC, breast and lung Upgrade to Smart Liquid Biopsy this year 15M+ <3% Patients Patients tested today 1 ACS Cancer Treatment & SurvivorshipFacts & Figures 2019-2021 2 Guardant assessment based on t
Slide 16: The future of MRD is tissue-free
The future of MRD is tissue-free Faster Easier Powerful Decreased initial turnaround No need for tissue access Ability to inform clinicians time to inform adjuvant for patients in the with precision, detection of decision making or to start neoadjuvant, adjuvant heterogeneous cancers, initial survei
Slide 17: Blazing a trail for a true liquid MRD test
Blazing a trail for a true liquid MRD test 1 2 3 Revolutionary Smart Liquid Biopsy Clinical validation on Leverage existing market- technology achieving high thousands of patients across leading oncology commercial sensitivity with ultra-high clinical dozens of tumor types to infrastructure to scale
Slide 18: Pioneering a new category of cancer screening
Pioneering a new category of cancer screening
Slide 19: Blood-based screening will change the cancer screening landscape
Blood-based screening will change the cancer screening landscape Metastatic 14% Survival Local Statistics from 26 different cancers comprising 87% of all cancers in U.S. 90% Survival Pleasant Consumer Regional Experience High Performance MCED Test 65% Survival Sources: SEER.cancer.gov. . Siegel, et
Slide 20: Successful screening requires both adherence and performance
Successful screening requires both adherence and performance 50M Unscreened 50K Colorectal cancer 76% of CRC deaths are in individuals1 deaths per year2,3 individuals not up to date with screening4 1. ACS Colorectal Cancer Facts 2020-2022 2. Bibbins-Domingo K, et al; JAMA. 2016;315(23):2564-2575. 3
Slide 21: Shield is the first easy to use, highly accurate blood-based cancer screening test
Shield is the first easy to use, highly accurate blood- based cancer screening test with proven efficacy in a pivotal trial 83% CRC Sensitivity 90% Specificity Guideline Recommendations 74-92% 87-96% • 100% sensitivity stage II and stage III/IV • 81% CRC sensitivity at stage I – III • 55% sensitivit
Slide 22: A new category of test will address the unmet need for patient preference
7 out of 10 Individuals who had a stool test would NOT choose stool again1 A new category of test will address the unmet need 5 to 1 for patient Unscreened individuals prefer blood over stool1 preference 90% Patient adherence to Shield LDT in >10K patients across >1,000 clinics2 1. 2022 Patient Segm
Slide 23: Blazing a trail to the first FDA approved and reimbursed CRC screening test
Blazing a trail to the first FDA approved and reimbursed CRC screening test Published Launched ECLIPSE Filed PMA staging data Launch Shield Medicare & ACS USPSTF Shield LDT Readout with FDA at DDW IVD-CRC ADLT Status Guidelines Guidelines May 2022 4Q’ 22 1Q’ 23 2Q’ 23 2024 2026 CRC Drives ADLT Prici
Slide 24: Next step to Multi-Cancer is adding lung indication
Next step to Multi-Cancer is adding lung indication Multi-Cancer … CRC + Lung CRC 24
Slide 25: Robust topline growth driven by precision oncology revenue
Robust topline growth driven by precision oncology revenue Total Revenue Precision Oncology Revenue $143M 22% 31% YoY Growth YoY Growth $133M $117M $102M Q3 2022 Q3 2023 Q3 2022 Q3 2023 25
Slide 26: Raised guidance for FY 2023 revenue
Raised guidance for FY 2023 revenue Revenue OpEx Free Cash Flow $553 – $556M < FY 2022 ~($350M) 23-24% y/y growth Leveraging existing Reducing cash infrastructure burn Raised from previous expectations of $545 - $550 million 26 Free cash outflow is defined as net cash used in operating activities pl
Slide 27: Transforming patient lives across the continuum of cancer care
Transforming patient lives across the continuum of cancer care Therapy Selection CMS reimbursement for Guardant Response Guardant360 reimbursement in Japan Ongoing rapid deployment of EMR customer integration Exceed 200M covered lives for TissueNext MRD / Recurrence Monitoring Screening First commer
Slide 28: () GUARDANT.
() GUARDANT.
Guardant Health — Jefferies London Healthcare Conference 2023 on 6ix